68 related articles for article (PubMed ID: 1580782)
1. Pressure sore anemia: response to erythropoietin.
Turba RM; Lewis VL; Green D
Arch Phys Med Rehabil; 1992 May; 73(5):498-500. PubMed ID: 1580782
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
4. [Recombinant erythropoietin in autologous blood donation].
von Bormann B; Weidler B; Friedrich M; von Andrian-Werburg H
Anaesthesist; 1991 Jul; 40(7):386-90. PubMed ID: 1928712
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
6. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
8. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
9. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
[TBL] [Abstract][Full Text] [Related]
10. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous recombinant human erythropoietin in patients on CAPD.
Lye WC; Lee EJ
Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
[TBL] [Abstract][Full Text] [Related]
12. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in hemodialysis patients using recombinant human erythropoietin: advantages and disadvantages].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1989 Mar; 119(9):269-75. PubMed ID: 2711161
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
15. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment of anemia in hemolysis patients using recombinant human erythropoietin. Maintenance dosage and serum concentration].
Stutz B; Rhyner K; Vögtli J; Binswanger U
Schweiz Med Wochenschr; 1987 Sep; 117(38):1397-402. PubMed ID: 3672079
[TBL] [Abstract][Full Text] [Related]
18. [Effects of rHuEPO on aplastic anemia: results of a phase II clinical study].
Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
Rinsho Ketsueki; 1993 Sep; 34(9):1002-10. PubMed ID: 8230742
[TBL] [Abstract][Full Text] [Related]
19. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]